<DOC>
	<DOCNO>NCT00258193</DOCNO>
	<brief_summary>- The primary objective trial compare dose-ranging pharmacodynamic effect orally administer placebo , 100 1000 ug qd MD-1100 Acetate gastrointestinal transit patient C-IBS . - The secondary objective trial : 1 . To compare dose range pharmacodynamic effect placebo , 100 1000 ug MD-1100 Acetate daily time first bowel movement first drug intake . 2 . To describe summarize effect placebo , 100 1000 ug MD-1100 Acetate daily stool frequency , stool consistency , ease passage sensation incomplete evacuation Treatment Period relative Baseline .</brief_summary>
	<brief_title>Phase 2 Study MD-1100 Acetate Gastrointestinal Transit Patients With C-IBS</brief_title>
	<detailed_description>Using double-blind , randomize , placebo-controlled , parallel group study design , effect placebo two different dos orally administer MD-1100 Acetate gastric emptying , small bowel transit total colonic transit compare evaluated patient C-IBS . After eligibility confirm , patient return baseline measurement colonic transit ensure transit profile great mean transit profile healthy control order avoid ceiling effect . A patient must geometric center ≤2.65 24 hour , ≤3.0 24 hour ≤3.9 48 hour order randomize 5-day Treatment Period study medication . Eligible patient receive oral study medication 5 day colonic transit measure . Approximately 36 ( n=36 ) patient randomize one three different treatment group : placebo ( n=12 ) , 100 ug MD-1100 ( n=12 ) , 1000 ug MD-1100 ( n=12 ) . All dose study medication supervise Mayo Clinic . Patients complete daily Stool Diary record bowel habit 5 consecutive day Pretreatment Period 5 consecutive day Treatment PeriodPhysical examination , vital sign , electrocardiogram , clinical laboratory test perform throughout study adverse event record safety evaluation .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Constipation</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<criteria>Patient agree use medically accept , doublebarrier form contraception ( e.g. , IUD condom ) participation ; No evidence pelvic floor dysfunction completion negative digital rectal exam prior first dose study medication ; Absence evacuation disorder define per protocol ; Patients must meet ROME II Criteria CIBS ; The patient ’ Baseline Colonic Transit Test must show geometric center ( GC ) ≤ 2.65 24 hour , ≤ 3.0 24 hour ≤ 3.9 48 hour . History clinicallysignificant manifestation major system organ class ; History inflammatory bowel disease gastric ulcer ; Significant GI surgery within 6 month ; Clinicallysignificant prolong diarrhea within 60 day ; Special dietary habit and/or intense physical workout program within 4 week ; Certain drug hypersensitivity History alcoholism drug addiction within 12 month ; Receipt investigational drug study within 30 day ; Use prescription medication OTC , nonprescription medication disallow protocol within 7 day .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2006</verification_date>
	<keyword>C-IBS</keyword>
	<keyword>IBS-C</keyword>
	<keyword>Constipation-predominant Irritable Bowel Syndrome</keyword>
	<keyword>Constipation Predominant Irritable Bowel Syndrome</keyword>
	<keyword>Irritable Bowel Syndrome</keyword>
	<keyword>IBS</keyword>
	<keyword>Transit</keyword>
	<keyword>Scintigraphy</keyword>
	<keyword>Gastroenterology</keyword>
	<keyword>Gastrointestinal</keyword>
	<keyword>GC</keyword>
	<keyword>MD-1100 Acetate</keyword>
	<keyword>MD-1100</keyword>
	<keyword>linaclotide</keyword>
	<keyword>linaclotide acetate</keyword>
</DOC>